Biotechnology cancer Cancer Discovery Cardiology Clinical Trials drug development Lung Cancer Cells Have Differential Signaling Responses to KRAS Inhibitor Treatment with Important Implications for Emerging Clinical Trials By Staff Reports 9 months ago Genetic alterations of the KRAS gene are some of the most common mutations in lung
Biotechnology cancer Cardiology Clinical Trials Gene Therapy Targeted inhibitor of mutated KRAS gene shows promise in early trial for lung, bowel, and other solid tumors By Staff Reports 1 year ago A novel agent that targets a mutated form of the KRAS gene – the most
Biotechnology cancer Clinical Trials drug development Immunotherapies Investigational Drug with Immunotherapy May Provide New Therapeutic Opportunity for Patients Previously Treated for Kidney and Lung Cancer By Staff Reports 2 years ago Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may
cancer Immunotherapies Immunotherapy drug improves five-year survival rate of people with advanced lung cancer By Staff Reports 3 years ago In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more
Medical Devices ProLung Announces Preliminary Results from its PL-208 Clinical Trial and Next-Steps By Staff Reports 3 years ago ProLung, Inc. which is focused on reducing the time to diagnosis for lung cancer patients
Biotechnology cancer Cancer screening A New Tool to Help Fight an Old Enemy – Lung Cancer By Staff Reports 3 years ago November is Lung Cancer Awareness Month and in the United States, lung cancer remains the
Cancer screening Doctor-patient discussions neglect potential harms of lung cancer screening, study finds By Staff Reports 3 years ago Although national guidelines advise doctors to discuss the benefits and harms of lung cancer screening
Biotechnology cancer Clinical Trials Uncategorized Brain metastases common and difficult to treat in ROS1 lung cancer By Staff Reports 3 years ago Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For
cancer Biomarker may help diagnose lung cancer earlier By Staff Reports 4 years ago (UPI) — High levels of a protein found in the bloodstreams of lung cancer patients
Biotechnology cancer Cell Therapy Drug Reduces Size of Some Lung Cancer Tumors, Relapse Rate After Surgery By Staff Reports 4 years ago A drug given to early stage lung cancer patients before they undergo surgery showed major
cancer Cancer Discovery Novel Clinical Tool to Predict Patient Survival Rate and Treatment Outcomes for Early-Stage Lung Cancer By Staff Reports 4 years ago A team of researchers, led by Professor Lim Chwee Teck from the Department of Biomedical
Pharmaceutical Business News Merck’s Keytruda helps lung cancer patients live longer in trial By Staff Reports 4 years ago Merck & Co’s blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in
Biotechnology cancer Cancer Discovery Uncategorized Identifying a New Therapeutic Target for the Most Common Type of Lung Cancer By Staff Reports 4 years ago Research by Rutgers Cancer Institute of New Jersey investigators has identified novel functions of the
Biotechnology cancer Cell Therapy Clinical Trials Immunotherapies Molecular Inhibitors Can Boost Natural Tumor Suppression to Fight Lung Cancer and Mesothelioma By Staff Reports 4 years ago Inhibition of the oncogenic kinase AKT, a key protein governing the cell cycle, was found
Cancer Discovery Thirdhand Smoke Found to Increase Lung Cancer Risk in Mice By Staff Reports 4 years ago Researchers at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) identified thirdhand smoke,
Pharmaceutical Business News FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing By Staff Reports 4 years ago The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients
Pharmaceutical Business News Merck KGaA and Pfizer’s Avelumab fails in trial By Staff Reports 4 years ago (Marketwatch) Merck KGaA and Pfizer Inc. said on Thursday that avelumab, a cancer immunotherapy, failed
cancer Cancer Discovery Early Evidence of Efficacy and Safety Seen in Novel Targeted Immunotherapy By Staff Reports 4 years ago An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy
cancer Making Milestones Against Non-Small Cell Lung Cancer By Staff Reports 4 years ago Hard to detect in its early stages and hard to treat as it advances, lung
cancer Placental Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study By Staff Reports 4 years ago According to the peer-reviewed article in the journal Scientific Reports, placenta-derived cells called PLX cells, exhibit